Home » Market News » DirectorsTalk Highlights » Crohn’s disease: Bowel condition is relatively common yet remains an invisible illness
4d Pharma Plc

Crohn’s disease: Bowel condition is relatively common yet remains an invisible illness

You’ve probably heard of Crohn’s diease, but do you really know what it means? For starters, it’s actually pretty common, every 30 minutes in the UK, someone is diagnosed with Crohn’s or ulcerative colitis, the two main forms of inflammatory bowel disease (IBD).

These are lifelong conditions that can have a big impact, but Crohn’s is often described as an ‘invisible illness’, because it’s not always apparent on the outside exactly what’s going on with somebody’s health. In other words, people might not ‘look’ as unwell as they are, which can contribute to lack of understanding and awareness.

People with Crohn’s disease commonly experience phases of intense abdominal pain, exhaustion, bloody diarrhoea, sore, swollen joints and a number of other unpleasant symptoms.

 

4D Pharma plc (LON:DDDD) is a world leader in the development of live biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacteria, that is applicable to the prevention, treatment or cure of a disease.

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.